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magnitude and nature of a life-threatening CVM are eval-
uated, is absolute ethanol sclerotherapy the lesser of two
evils? To answer these questions we must examine the
approach followed by Lee’s group and assess the thera-
peutic alternatives available.
The multiple clinical forms of CVM and the diverse
terms given to seemingly similar clinical manifestations have
made it difficult to analyze scientific communications about
these diseases. The need of a uniform classification was evi-
dent. A classification based on the correlation between the
biologic nature of the malformation and its clinical presen-
tation was published in 1982.1 Further refinements led to
the Hamburg classification in 1988.2,3 There must be a
team of specialists dedicated to the study and treatment of
vascular malformations in a referral center to properly clas-
sify an anomaly. This concept is not new because no single
individual has the necessary expertise to cover all aspects of
the diagnosis and treatment of complex forms of malforma-
tions. The evolving fields of diagnostics, therapy, and inves-
tigation require the collaboration of a group of experts
who, properly coordinated, work for the benefit of the
patient and the advancement of our knowledge. The large
series of patients with CVM studied in the South Korean
referral center for vascular malformations by an organized
multidisciplinary team of specialists after an established pro-
tocol represent an important contribution to this field.
Identification of the type of vascular tissue involved is
essential to select the proper form of treatment. Is the
CVM arterial, venous or lymphatic? Or is it a mixed CVM?
Diagnosis can be made in most cases with a carefully taken
clinical history of the patient and a physical examination.
Some CVMs are apparently circumscribed but may have
distant hidden localizations. The use of magnetic reso-
nance imaging and special imaging techniques such as sin-
gle photon emission computed tomography, which
documents the area’s blood flow, and positron emission
tomography with its potential to assess cerebral function4
have contributed to the expansion of our diagnostic capa-
bilities to demonstrate the extent of tissues involved and
the presence of often hidden localizations.5 In Lee et al’s
paper, in addition to clinical, angiographic, and magnetic
resonance imaging evaluation, whole body blood pool
Primum non nocere. For centuries, this has been the
golden rule guiding the practice of medicine and our ther-
apeutic approach to disease. In few conditions of human
pathology has this principle been more challenged than in
the management of complex forms of congenital vascular
malformations (CVMs). The severe involvement of vital
anatomic structures, such as eyes, mouth, and larynx, and
the widespread physical and psychological consequences
that often accompany some circumscribed and most dif-
fuse forms of CVM result in a serious threat to life and
function and constitute a formidable therapeutic chal-
lenge. In this issue, Lee et al report on their vast experi-
ence with the management of CVM accumulated in a
relatively short time (April 1996 to September 1998).
From a total of 318 patients, there were 143 (45%) who
predominantly had venous malformations. Most (78%)
were diffuse (“infiltrating” in the Hamburg classification).
Thirty of the 143 patients had symptoms and signs severe
enough to warrant aggressive treatment. Despite its rec-
ognized morbidity, the authors selected absolute alcohol
as their preferred sclerosant. Complications related to the
procedure developed in 26.7% of the patients (8/30). The
severity of the complications varied from moderate to
severe. They consisted of ischemic bullae, tissue fibrosis,
deep venous thrombosis, pulmonary embolism, peripheral
nerve palsy, and pulmonary hypertension. All recovered
completely, except one patient with peroneal nerve palsy.
There was no recurrence or deterioration of fair to good
results in 96% of the patients in a mean follow-up period
of 10.2 months. From the analysis of this and other series,
it is evident that there is a price to pay in the treatment of
complex CVMs with absolute ethanol. Is the price too
high? Is this form of treatment worth the risk? When the
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scan, which is a radioisotope study with labeled red blood
cells, has been instrumental not only in identifying and
localizing multiple lesions, but also in assessing the results
of therapy. The analysis of the diagnostic studies revealed
that there were 30 patients with severe symptomatic mal-
formations6,7 whose lesions either were nonresectable or
were in a surgically nonaccessible anatomical region.
Despite its well-recognized complications, which
include pulmonary embolism and death,8-10 and the need
for costly, repeated treatments with the patient under gen-
eral anesthesia, (98 sessions in 30 patients), absolute ethanol
was selected because in the authors’ opinion the intense
endothelial devitalization produced had more possibilities of
long-term success than with other sclerosants. A brief review
of the therapeutic alternatives in CVM is in order.
In small children with large, rapidly growing heman-
giomas involving vital structures (eyes, airway) with ulcera-
tion or bleeding, systemic corticoids should be the initial
form of treatment4 (we do not know how many small chil-
dren were in Lee et al’s study). Because hemangiomas are
angiogenic tumors, they respond well to antiangiogenic
pharmacotherapy. In localized lesions such as lips, nose and
eyelids, intralesional corticoids are effective.11 Subcu-
taneous, daily, recombinant interferon-α (2a or 2b) should
be considered in life-endangering hemangiomas that do not
respond to corticoids.12 Surgery is indicated in most forms
of localized arteriovenous malformation or in localized
lesions that do not respond to pharmacologic therapy.13
Laser therapy has a definitive role in the treatment of some
forms of infantile hemangiomas and especially in capillary
malformations.14 Failure of medical therapy in the treat-
ment of complications such as hemorrhage, Kassabach-
Merrit phenomenon, respiratory obstruction, and heart
failure is an indication for arterial embolization with small
particles. Depending on the size of the arteriovenous
shunts, tissue glues or microcoils delivered with superselec-
tive techniques and avoiding proximal vessel occlusion are
effective in controlling symptoms.15
Sclerotherapy has been used in the treatment of vari-
cose veins for more than 100 years. It is the preferred
method of treatment for CVM of venous predominance.
Sclerosants destroy the vascular endothelium through dif-
ferent mechanisms: chemical agents (iodine, variglobin,
ethanol), osmotic agents (salicylates, hypertonic saline,
hypertonic glucose), and detergents, which change the
surface tension of the cell-producing tissue maceration
(sodium morrhuate, Sotradecol, ethanolamine, polido-
canol). de Lorimier16 used absolute ethanol and especially
sodium morrhuate in the treatment of 34 patients with
CVM of venous predominance.16 With patients under
general anesthesia, he injected from 5 to 90 mL of the
sclerosant directly into the nidus of the lesion. Some
patients with laryngeal lesions required preliminary tra-
cheostomy and ventilatory support. Complications
included a painful postsclerotherapy recovery, skin necro-
sis, nerve palsy, anaphylaxis, and hemoglobinuria. Large
extensive lesions required up to 30 sessions and several
years of treatment. In Lee et al’s series, similar complica-
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tions occurred with the direct injection of small amounts
of absolute ethanol into the nidus of the arteriovenous
malformation. Sclerotherapy or injection of adhesive glue
is often used before excisional surgery to reduce tumor
mass and bleeding. In visceral malformations not accessi-
ble through percutaneous catheterization, sclerotherapy of
the lesion during surgery is an excellent option.15
There is no safe sclerosant. All have complications of dif-
ferent degrees of severity. We must carefully weigh the risk-
benefit of a dangerous procedure against the severity of the
clinical problem of the patient. We must thoroughly inform
the patient and the family of the nature of the possible com-
plications. Often, we must choose sclerotherapy as the lesser
of the two evils! However, the use of aggressive agents, such
as absolute ethanol, must always be done by well-trained
interventional professionals in a dedicated center for the
study and care of patients with vascular malformations. The
decision to use absolute ethanol must also be the result of a
consensus of specialists with expertise in CVM.
In the future, we should stimulate the creation of cen-
ters with teams of specialists interested in the study and
treatment of vascular malformations. Neoangiogenesis is
being fully investigated, and new antiangiogenic drugs will
be available in the future. The mechanisms involved in the
development of vascular malformations are being investi-
gated, taking advantage of the extraordinary progress of
genetic engineering and molecular biology. In the clinical
arena, less aggressive forms of effective sclerosants are in
sight. The endovascular introduction of an active scle-
rosant mixed with gas (oxygen, carbon dioxide, or room
air) has been found effective in the treatment of patients
with diffuse, predominantly venous, superficial, and deep
CVMs. The resulting foam allows the sclerosing agent to
come in contact with more endothelial surface than the
liquid form, and a less amount of the sclerosant is used.17
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